Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 50009946
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533691(CHEMBL4466236)
Affinity DataIC50: 0.240nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095952(CHEMBL3593777)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533681(CHEMBL4591633)
Affinity DataIC50: 0.360nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533691(CHEMBL4466236)
Affinity DataIC50: 0.390nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533680(CHEMBL4455068)
Affinity DataIC50: 0.460nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533687(CHEMBL4463043)
Affinity DataIC50: 0.610nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533683(CHEMBL4454640)
Affinity DataIC50: 0.720nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533682(CHEMBL4463436)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533686(CHEMBL4470355)
Affinity DataIC50: 1nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533691(CHEMBL4466236)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533685(CHEMBL4471707)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095955(CHEMBL3593771)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533686(CHEMBL4470355)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533683(CHEMBL4454640)
Affinity DataIC50: 2.5nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533680(CHEMBL4455068)
Affinity DataIC50: 2.90nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533681(CHEMBL4591633)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095952(CHEMBL3593777)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533682(CHEMBL4463436)
Affinity DataIC50: 3.5nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533687(CHEMBL4463043)
Affinity DataIC50: 3.5nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533686(CHEMBL4470355)
Affinity DataIC50: 4nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533683(CHEMBL4454640)
Affinity DataIC50: 4.10nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095952(CHEMBL3593777)
Affinity DataIC50: 4.10nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533682(CHEMBL4463436)
Affinity DataIC50: 4.20nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533680(CHEMBL4455068)
Affinity DataIC50: 4.90nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095984(CHEMBL3593761)
Affinity DataIC50: 5.10nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533685(CHEMBL4471707)
Affinity DataIC50: 5.30nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533681(CHEMBL4591633)
Affinity DataIC50: 5.40nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533687(CHEMBL4463043)
Affinity DataIC50: 5.5nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533685(CHEMBL4471707)
Affinity DataIC50: 6.70nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095955(CHEMBL3593771)
Affinity DataIC50: 16nMAssay Description:Inhibition of human JAK1 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095955(CHEMBL3593771)
Affinity DataIC50: 18nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533690(CHEMBL4474752)
Affinity DataIC50: 18nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50261771(CHEMBL4072239)
Affinity DataIC50: 19nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533688(CHEMBL4476828)
Affinity DataIC50: 22nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533684(CHEMBL4523034)
Affinity DataIC50: 25nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533693(CHEMBL4446468)
Affinity DataIC50: 37nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533684(CHEMBL4523034)
Affinity DataIC50: 130nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533690(CHEMBL4474752)
Affinity DataIC50: 190nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533680(CHEMBL4455068)
Affinity DataIC50: 360nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533688(CHEMBL4476828)
Affinity DataIC50: 400nMAssay Description:Inhibition of human JAK2 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533689(CHEMBL4583335)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533692(CHEMBL4579428)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human JAK3 assessed as reduction in phosphorylation of Biotin-Lyn-Substrate-2 after 1 hr in presence of ATP by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533685(CHEMBL4471707)
Affinity DataIC50: 4.80E+3nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533686(CHEMBL4470355)
Affinity DataIC50: 5.40E+3nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533688(CHEMBL4476828)
Affinity DataIC50: 6.60E+3nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533683(CHEMBL4454640)
Affinity DataIC50: 7.70E+3nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533681(CHEMBL4591633)
Affinity DataIC50: 8.10E+3nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50095955(CHEMBL3593771)
Affinity DataIC50: 1.34E+4nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533687(CHEMBL4463043)
Affinity DataIC50: 1.70E+4nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astellas Pharma

Curated by ChEMBL
LigandPNGBDBM50533682(CHEMBL4463436)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human ERG expressed in CHO-K1 cells after 10 mins by Rb efflux assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: